ProCE Banner Activity

CE / CME

African Immigrant People: Overcoming HBV Barriers

Video

Hear patient and faculty insights as they discuss barriers to effective HBV care for African immigrant people, including HBV awareness and misperceptions, HBV-related stigma, language, and insurance navigation, along with practical solutions to overcome these barriers.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 25, 2023

Expiration: May 24, 2024

Share

Faculty

Essa Mohamed

Essa Mohamed, PhD

Clinical Researcher
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Daouda Ndiaye

Daouda Ndiaye

Patient Navigator

Ponni Perumalswami

Ponni Perumalswami, MD, MS

Associate Professor of Internal Medicine
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC in partnership with Asian Health Foundation and Hepatitis B Foundation 

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc. 

Gilead Sciences, Inc.

Partners

AHF

ProCE Banner

Hepatitis B Foundation

ProCE Banner

Target Audience

This program is intended for physicians, pharmacists, nurses, and other HCPs who care for patients with HBV.

Program Learning Goal

To improve learners’ competence in overcoming unique barriers to implementation of optimized HBV care in key communities.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize barriers that hamper engagement across the HBV care continuum for African immigrant people, including screening, treatment initiation, monitoring, and sustained therapy.

  • Develop strategies to overcome unique cultural barriers to HBV care within African immigrant communities in the United States

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Essa Mohamed, PhD

Clinical Researcher
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Essa Mohamed, PhD, has no relevant financial relationships to disclose.

Contributing Author

Daouda Ndiaye,

Patient Navigator

Daouda Ndiaye has no relevant financial relationships to disclose.

Ponni Perumalswami, MD, MS

Associate Professor of Internal Medicine
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan

Ponni Perumalswami, MD, MS, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC, Asian Health Foundation, and Hepatitis B Foundation have no relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 25, 2023, through May 24, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), Asian Health Foundation, and Hepatitis B Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour. 

Continuing Pharmacy Education


CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-140-H01-P 

Type of Activity
: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.